newsfilter
← Latest News
Business Wire·

Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis

—Topline data expected by February 2022— —Prithviraj Bose, MD, to join Sierra Oncology Leadership to discuss importance of treating anemia in myelofibrosis patients— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical compa